Reports

Sale

Warm Autoimmune Hemolytic Anemia Market Size, Share, Growth: By Drug Class: Fostamatinib, Sutimlimab, Parsaclisib, Rilzabrutinib, Isatuximab; By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies; Regional Analysis; Market Dynamics: Market Drivers and Constraints; Supplier Landscape; 2024-2032

Warm Autoimmune Hemolytic Anemia Market Outlook

The warm autoimmune hemolytic anemia market size is expected to grow at a CAGR of 15.9% during the forecast period of 2024-2032, driven by the heightened awareness surrounding autoimmune diseases along with the growing research initiatives focused on the development of novel therapies across the 8 major markets.

Warm Autoimmune Hemolytic Anemia Market Overview

Warm autoimmune hemolytic anemia (wAIHA) is considered the most common type of autoimmune hemolytic anemia, affecting about 1 to 3 adults in every 100,000 individuals . The autoimmune disorder is caused by autoantibodies that react with self-red blood cells (RBCs) and destroy them, resulting in anemia. These antibodies are active at body temperature and are present in 80% of the cases. It particularly targets older red blood cells.

Autoimmune hemolytic anemia usually occurs among older adults, with the majority of the patients aged 40 or above at the time of diagnosis. The rise in the geriatric population size is expected to drive the warm autoimmune hemolytic anemia market demand, as more and more elderly patients will need effective therapeutics to manage the condition. Moreover, the growing awareness among patients as well as healthcare providers is encouraging treatment-seeking behaviour, improving diagnosis rates, and ultimately propelling market growth.

The market is driven by increasing research initiatives to develop and commercialize safer and more effective treatment therapies to manage this autoimmune disorder. In November 2023, a study published in the American Journal of Hematology revealed Phase 3 FORWARD trial results of Fostamatinib (an oral spleen tyrosine kinase inhibitor) for warm autoimmune hemolytic anemia patients. The data suggested clinically significant outcomes for the patients in North America, Australia, and Western Europe, indicating the potential of fostamatinib in inducing durable hemoglobin responses. The increased number of clinical trials will aid in bringing promising treatment solutions to the rising patient population, thereby supporting warm autoimmune hemolytic anemia market growth.

The market is witnessing increased collaboration and partnerships among the key market players as well as research institutes. This accelerates development and innovation in the treatment landscape. The market is also driven by favourable regulatory reforms by the health agencies such as the United States Food and Drug Administration (FDA) which helps in addressing the clinical needs of patients suffering from warm autoimmune hemolytic anemia. Moreover, the rising technological innovation in diagnostics and the increased healthcare expenditure will fuel market growth in the coming years.

Warm Autoimmune Hemolytic Anemia Market Trends

Key Trend	Impact
Advancements in Treatment Options	The development of new therapies and treatment options has elevated the market value. Novel treatments which target specific pathways involved in the autoimmune response are exhibiting positive results in clinical trials, offering promising alternatives to traditional corticosteroids and splenectomy, which are associated with certain side effects and risks. These advancements improve efficacy and patient outcomes and drive market growth by addressing the unmet clinical need for safe and effective treatment options.
Technological Innovations in Diagnostics	The warm autoimmune hemolytic anemia market share is further propelled by the advent of technological advancements in diagnostic technologies such as next-generation sequencing and advanced immunophenotyping are facilitating quick and accurate identification and classification of the condition. These technologies enable a more precise understanding of the cause of the disease, aiding in personalized treatment approaches. By improving diagnostic accuracy and speed, technological innovations enhance patient care and help in identifying a larger patient population eligible for targeted treatments, thereby driving market demand.
Rising Patient Awareness and Diagnosis Rates	One of the significant warm autoimmune hemolytic anemia market trends is the heightened awareness among healthcare providers and the public about autoimmune hemolytic anemias, including warm autoimmune hemolytic anemia, which has led to higher diagnosis rates. Early and accurate diagnosis lays the foundation for effective management of the disease, reducing the risk of severe complications. This trend is driving demand for diagnostic and therapeutic options, attracting investment in research and development, and consequently boosting market growth.
Favourable Regulatory and Reimbursement Frameworks	Changes in regulatory policies and reimbursement frameworks significantly impact the market landscape. Faster regulatory approvals for innovative treatments enhance market access and patient adoption rates. Moreover, favorable reimbursement policies for new and existing therapies ensure that more patients can afford these life-saving treatments, thereby expanding the market size. This regulatory and reimbursement support also encourages pharmaceutical companies to invest in the development of new therapies, ultimately driving growth in the market.

Warm Autoimmune Hemolytic Anemia Market Segmentation

Market Breakup by Drug Class

Fostamatinib

Sutimlimab

Parsaclisib

Rilzabrutinib

Isatuximab

The market is segmented by drug class into Fostamatinib, Sutimlimab, Parsaclisib, Rilzabrutinib, and Isatuximab. This segment covers various therapeutic options available in the market for managing warm autoimmune hemolytic anemia.

Market Breakup by Distribution Channel

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

In terms of distribution channels, the warm autoimmune hemolytic anemia market share comprises hospital pharmacies, online pharmacies, and retail pharmacies. These channels offer a robust network to facilitate access to medications for patients with this autoimmune disorder according to their needs and convenience.

Market Breakup by Region

United States

EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom

Japan

India

Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. The United States leads the market share, owing to the high prevalence of autoimmune diseases in the region including warm autoimmune hemolytic anemia. Further, the presence of an advanced healthcare infrastructure fuels the development of novel therapeutics and diagnostics tools for the treatment of this autoimmune disorder. Other factors that propel the market growth are the increasing investment in the healthcare industry and growing research activities in the regional market.

Warm Autoimmune Hemolytic Anemia Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Rigel Pharmaceuticals

Apellis Pharmaceuticals, Inc.

Johnson & Johnson

Sanofi

Incyte Corporation

Momenta Pharmaceuticals

Teva Pharmaceuticals Ltd.

F. Hoffmann La Roche Ltd.

Alexion Pharmaceuticals Inc.

Immunovant

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES	DETAILS
Base Year	2023
Historical Period	2017-2023
Forecast Period	2024-2032
Scope of the Report	Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment: Drug Class Distribution Channel Region
Breakup by Drug Class	Fostamatinib Sutimlimab Parsaclisib Rilzabrutinib Isatuximab
Breakup by Distribution Channel	Hospital Pharmacies Online Pharmacies Retail Pharmacies
Breakup by Region	United States EU-4 and the United Kingdom Japan India
Market Dynamics	Market Drivers and Constraints SWOT Analysis Porter’s Five Forces Model Key Demand Indicators Key Price Indicators Industry Events, Initiatives, and Trends Value Chain Analysis
Supplier Landscape	Market Structure Company Profiles Financial Analysis Product Portfolio Demographic Reach and Achievements Mergers and Acquisitions Certifications
Companies Covered	Rigel Pharmaceuticals Apellis Pharmaceuticals, Inc. Johnson & Johnson Sanofi Incyte Corporation Momenta Pharmaceuticals Teva Pharmaceuticals Ltd. F. Hoffmann La Roche Ltd. Alexion Pharmaceuticals Inc. Immunovant

Key Queries Solved in the Warm Autoimmune Hemolytic Anemia Market Report

How has the market performed so far and how will it perform in the coming years?
What are the major market trends influencing the market?
What are the market's major drivers, opportunities, and restraints?
What will be the effect of each driver, challenge, and opportunity on the market?
Which regional market is expected to lead the market share in the forecast period?
Which country is expected to experience expedited growth during the forecast period?
How does the prevalence and incidence of warm autoimmune hemolytic anemia affect the market landscape?
How do the advancements in treatment options impact the warm autoimmune hemolytic anemia market size?
Which drug class will dominate the market share?
Which distribution channel is expected to have a high market value in the coming years?
How will the ongoing clinical trials impact market growth during the forecast period?
What are the factors driving regional disparities in warm autoimmune hemolytic anemia treatment and outcomes?
What are the current unmet needs and challenges in the market?
How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1   Preface
   1.1   Objectives of the Study
   1.2   Key Assumptions
   1.3   Report Coverage – Key Segmentation and Scope
   1.4   Research Methodology
2   Executive Summary
3   Warm Autoimmune Hemolytic Anemia Market Overview – 8 Major Markets
   3.1   Warm Autoimmune Hemolytic Anemia Market Historical Value (2017-2023)
   3.2   Warm Autoimmune Hemolytic Anemia Market Forecast Value (2024-2032)
4   Warm Autoimmune Hemolytic Anemia Overview
   4.1   Guidelines and Stages
   4.2   Pathophysiology
   4.3   Screening and Diagnosis
   4.4   Treatment Pathway
5   Patient Profile
   5.1   Patient Profile Overview
   5.2   Patient Psychology and Emotional Impact Factors
   5.3   Risk Assessment and Treatment Success Rate
6   Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast – 8 Major Markets
   6.1   8MM Epidemiology Scenario Overview (2017-2032)
   6.2   United States Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
   6.3   EU-4 and United Kingdom Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
       6.3.1   Germany Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
       6.3.2   France Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
       6.3.3   Italy Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
       6.3.4   Spain Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
       6.3.5   United Kingdom Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
   6.4   Japan Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
   6.5   India Warm Autoimmune Hemolytic Anemia Epidemiology Scenario and Forecast (2017-2032)
7   Warm Autoimmune Hemolytic Anemia Market Landscape – 8 Major Markets
   7.1   Warm Autoimmune Hemolytic Anemia: Developers Landscape
       7.1.1   Analysis by Year of Establishment
       7.1.2   Analysis by Company Size
       7.1.3   Analysis by Region
   7.2   Warm Autoimmune Hemolytic Anemia: Product Landscape
       7.2.1   Analysis by Drug Class
       7.2.2   Analysis by Distribution Channel
8   Warm Autoimmune Hemolytic Anemia Challenges and Unmet Needs
   8.1   Treatment Pathway Challenges
   8.2   Compliance and Drop-Out Analysis
   8.3   Awareness and Prevention Gaps
9   Cost of Treatment
10   Warm Autoimmune Hemolytic Anemia Market Dynamics
   10.1   Market Drivers and Constraints
   10.2   SWOT Analysis
   10.3   Porter’s Five Forces Model
   10.4   Key Demand Indicators
   10.5   Key Price Indicators
   10.6   Industry Events, Initiatives, and Trends
   10.7   Value Chain Analysis
11   Warm Autoimmune Hemolytic Anemia Market Segmentation (2017-2032) - 8 Major Markets
   11.1   Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Drug Class
       11.1.1   Market Overview
       11.1.2   Fostamatinib
       11.1.3   Sutimlimab
       11.1.4   Parsaclisib
       11.1.5   Rilzabrutinib
       11.1.6   Isatuximab
   11.2   Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Distribution Channel
       11.2.1   Market Overview
       11.2.2   Hospital Pharmacies
       11.2.3   Online Pharmacies
       11.2.4   Retail Pharmacies
   11.3   Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Region
       11.3.1   Market Overview
       11.3.2   United States
       11.3.3   EU-4 and the United Kingdom
           11.3.3.1   Germany
           11.3.3.2   France
           11.3.3.3   Italy
           11.3.3.4   Spain
           11.3.3.5   United Kingdom
       11.3.4   Japan
       11.3.5   India
12   United States Warm Autoimmune Hemolytic Anemia Market (2017-2032)
   12.1   United States Warm Autoimmune Hemolytic Anemia Market Historical Value (2017-2023)
   12.2   United States Warm Autoimmune Hemolytic Anemia Market Forecast Value (2024-2032)
   12.3   United States Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Drug Class
       12.3.1   Market Overview
       12.3.2   Fostamatinib
       12.3.3   Sutimlimab
       12.3.4   Parsaclisib
       12.3.5   Rilzabrutinib
       12.3.6   Isatuximab
13   EU-4 and United Kingdom Warm Autoimmune Hemolytic Anemia Market (2017-2032)
   13.1   EU-4 and United Kingdom Warm Autoimmune Hemolytic Anemia Market Historical Value (2017-2023)
   13.2   EU-4 and United Kingdom Warm Autoimmune Hemolytic Anemia Market Forecast Value (2024-2032)
   13.3   EU-4 and United Kingdom Warm Autoimmune Hemolytic Anemia Market Overview
   13.4   EU-4 and United Kingdom Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Drug Class
       13.4.1   Market Overview
       13.4.2   Fostamatinib
       13.4.3   Sutimlimab
       13.4.4   Parsaclisib
       13.4.5   Rilzabrutinib
       13.4.6   Isatuximab
14   Japan Warm Autoimmune Hemolytic Anemia Market
   14.1   Japan Warm Autoimmune Hemolytic Anemia Market Historical Value (2017-2023)
   14.2   Japan Warm Autoimmune Hemolytic Anemia Market Forecast Value (2024-2032)
   14.3   Japan Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Drug Class
       14.3.1   Market Overview
       14.3.2   Fostamatinib
       14.3.3   Sutimlimab
       14.3.4   Parsaclisib
       14.3.5   Rilzabrutinib
       14.3.6   Isatuximab
15   India Warm Autoimmune Hemolytic Anemia Market
   15.1   India Warm Autoimmune Hemolytic Anemia Market (2017-2032) Historical Value (2017-2023)
   15.2   India Warm Autoimmune Hemolytic Anemia Market (2017-2032) Forecast Value (2024-2032)
   15.3   India Warm Autoimmune Hemolytic Anemia Market (2017-2032) by Drug Class
       15.3.1   Market Overview
       15.3.2   Fostamatinib
       15.3.3   Sutimlimab
       15.3.4   Parsaclisib
       15.3.5   Rilzabrutinib
       15.3.6   Isatuximab
16   Regulatory Framework
   16.1   Regulatory Overview
       16.1.1   US FDA
       16.1.2   EU EMA
       16.1.3   Japan PMDA
       16.1.4   Others
17   Patent Analysis
   17.1   Analysis by Type of Patent
   17.2   Analysis by Publication Year
   17.3   Analysis by Issuing Authority
   17.4   Analysis by Patent Age
   17.5   Analysis by CPC Analysis
   17.6   Analysis by Patent Valuation
   17.7   Analysis by Key Players
18   Grants Analysis
   18.1   Analysis by Year
   18.2   Analysis by Amount Awarded
   18.3   Analysis by Issuing Authority
   18.4   Analysis by Grant Application
   18.5   Analysis by Funding Institute
   18.6   Analysis by NIH Departments
   18.7   Analysis by Recipient Organization
19   Clinical Trials Analysis
   19.1   Analysis by Trial Registration Year
   19.2   Analysis by Trial Status
   19.3   Analysis by Trial Phase
   19.4   Analysis by Therapeutic Area
   19.5   Analysis by Geography
20   Funding and Investment Analysis
   20.1   Analysis by Funding Instances
   20.2   Analysis by Type of Funding
   20.3   Analysis by Funding Amount
   20.4   Analysis by Leading Players
   20.5   Analysis by Leading Investors
   20.6   Analysis by Geography
21   Partnership and Collaborations Analysis
   21.1   Analysis by Partnership Instances
   21.2   Analysis by Type of Partnership
   21.3   Analysis by Leading Players
   21.4   Analysis by Geography
22   Supplier Landscape
   22.1   Rigel Pharmaceuticals
       22.1.1   Financial Analysis
       22.1.2   Product Portfolio
       22.1.3   Demographic Reach and Achievements
       22.1.4   Mergers and Acquisitions
       22.1.5   Certifications
   22.2   Apellis Pharmaceuticals, Inc.
       22.2.1   Financial Analysis
       22.2.2   Product Portfolio
       22.2.3   Demographic Reach and Achievements
       22.2.4   Mergers and Acquisitions
       22.2.5   Certifications
   22.3   Johnson & Johnson
       22.3.1   Financial Analysis
       22.3.2   Product Portfolio
       22.3.3   Demographic Reach and Achievements
       22.3.4   Mergers and Acquisitions
       22.3.5   Certifications
   22.4   Sanofi
       22.4.1   Financial Analysis
       22.4.2   Product Portfolio
       22.4.3   Demographic Reach and Achievements
       22.4.4   Mergers and Acquisitions
       22.4.5   Certifications
   22.5   Incyte Corporation
       22.5.1   Financial Analysis
       22.5.2   Product Portfolio
       22.5.3   Demographic Reach and Achievements
       22.5.4   Mergers and Acquisitions
       22.5.5   Certifications
   22.6   Momenta Pharmaceuticals
       22.6.1   Financial Analysis
       22.6.2   Product Portfolio
       22.6.3   Demographic Reach and Achievements
       22.6.4   Mergers and Acquisitions
       22.6.5   Certifications
   22.7   Teva Pharmaceuticals Ltd.
       22.7.1   Financial Analysis
       22.7.2   Product Portfolio
       22.7.3   Demographic Reach and Achievements
       22.7.4   Mergers and Acquisitions
       22.7.5   Certifications
   22.8   F. Hoffmann La Roche Ltd.
       22.8.1   Financial Analysis
       22.8.2   Product Portfolio
       22.8.3   Demographic Reach and Achievements
       22.8.4   Mergers and Acquisitions
       22.8.5   Certifications
   22.9   Alexion Pharmaceuticals Inc.
       22.9.1   Financial Analysis
       22.9.2   Product Portfolio
       22.9.3   Demographic Reach and Achievements
       22.9.4   Mergers and Acquisitions
       22.9.5   Certifications
   22.10   Immunovant
       22.10.1   Financial Analysis
       22.10.2   Product Portfolio
       22.10.3   Demographic Reach and Achievements
       22.10.4   Mergers and Acquisitions
       22.10.5   Certifications
23   Warm Autoimmune Hemolytic Anemia Treatment Drugs - Distribution Model (Additional Insight)
   23.1   Overview
   23.2   Potential Distributors
   23.3   Key Parameters for Distribution Partner Assessment
24   Key Opinion Leaders (KOL) Insights (Additional Insight)
25   Company Competitiveness Analysis (Additional Insight)
   25.1   Very Small Companies
   25.2   Small Companies
   25.3   Mid-Sized Companies
   25.4   Large Companies
   25.5   Very Large Companies
26   Payment Methods (Additional Insight)
   26.1   Government Funded
   26.2   Private Insurance
   26.3   Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Key Questions Answered in the Report

What is the warm autoimmune hemolytic anemia market forecast outlook for 2024-2032?

The market is anticipated to grow at a CAGR of 15.9% during the forecast period of 2024-2032, driven by the heightened awareness surrounding autoimmune diseases across the 8 major markets.

What are the major factors aiding the warm autoimmune hemolytic anemia market demand?

The market demand is driven by increased healthcare expenditure and improved access to healthcare products and services.

What are the major warm autoimmune hemolytic anemia market trends?

One of the significant trends in the market is increasing research initiatives to develop and commercialize safer and more effective treatment therapies to manage the condition. In November 2023, Phase 3 FORWARD trial results of Fostamatinib showed promising results for warm autoimmune hemolytic anemia patients.

What is the market segmentation based on the drug class?

Based on the drug class, the market is segmented into Fostamatinib, Sutimlimab, Parsaclisib, Rilzabrutinib, and Isatuximab.

What are the distribution channels in the market?

Distribution channels in the market include hospital pharmacies, online pharmacies, and retail pharmacies.

What are the major regional markets for warm autoimmune hemolytic anemia, according to the EMR report?

The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India.

Who are the key players involved in the warm autoimmune hemolytic anemia market?

Key players involved in the market are Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Johnson & Johnson, Sanofi, Incyte Corporation, Momenta Pharmaceuticals, Teva Pharmaceuticals Ltd., F. Hoffmann La Roche Ltd., Alexion Pharmaceuticals Inc., and Immunovant.

Request Sample

Purchase Full Report

Mini Report

$ ~~3299~~ $2999

Selected Sections, One User
Printing Not Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Single User License

$ ~~6599~~ $5999

All Sections, One User
One Print Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Five User License

$ ~~8799~~ $7999

All Sections, Five Users
Five Prints Allowed
Email Delivery in PDF
Free Limited Customisation
Post Sales Analyst Support
~~50% Discount on Next Update~~

Buy Now

Corporate License

$ ~~9899~~ $8999

All Sections, Unlimited Users
Unlimited Prints Allowed
Email Delivery in PDF + Excel
Free Limited Customisation
Post Sales Analyst Support
50% Discount on Next Update

Buy Now

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER